



Sup. Fig. 1. SymN differentiation protocol and improvements (related to Fig. 1)




Sup Fig 2. SymN purity and functionality (related to Fig. 1)




Sup Fig 3. FD iPSC characterization (related to Fig. 1)

a




Sup Fig 4. Characterization of contaminating cell types in FD at the NCC stage (related to Fig. 1)




Sup Fig 5. FD symNs are hyperactive (related to Fig. 2)


a day 7 beating CMs




b




c



d




e




Sup Fig 6. FD animals (related to Fig. 3)


a



b



c



Sup. Fig. 7. Support for mini drug screen (related to fig. 5)

